Cargando…

Peony-Glycyrrhiza Decoction for Antipsychotic-Related Hyperprolactinemia in Patients with Schizophrenia: A Randomized Controlled Trial

BACKGROUND: Most antipsychotic drugs are dopamine receptor antagonists that usually lead to abnormal increases in prolactin concentrations and the development of hyperprolactinemia (HPRL), which in turn causes sexual dysfunction in patients. Peony-Glycyrrhiza Decoction (PGD) enhanced dopamine D2 rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhongbao, Zheng, Yunshao, Fan, Yunli, Fan, Yunming, Su, Xianbiao, Wang, Bingrui, Li, Jing, Chen, Diancai, Sun, Fengxia, Li, Shen, Ma, Jiashu, Li, Xianwei, Bai, Ludong, Li, Ranran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120814/
https://www.ncbi.nlm.nih.gov/pubmed/37089913
http://dx.doi.org/10.2147/NDT.S408314
_version_ 1785029248701956096
author Wang, Zhongbao
Zheng, Yunshao
Fan, Yunli
Fan, Yunming
Su, Xianbiao
Wang, Bingrui
Li, Jing
Chen, Diancai
Sun, Fengxia
Li, Shen
Ma, Jiashu
Li, Xianwei
Bai, Ludong
Li, Ranran
author_facet Wang, Zhongbao
Zheng, Yunshao
Fan, Yunli
Fan, Yunming
Su, Xianbiao
Wang, Bingrui
Li, Jing
Chen, Diancai
Sun, Fengxia
Li, Shen
Ma, Jiashu
Li, Xianwei
Bai, Ludong
Li, Ranran
author_sort Wang, Zhongbao
collection PubMed
description BACKGROUND: Most antipsychotic drugs are dopamine receptor antagonists that usually lead to abnormal increases in prolactin concentrations and the development of hyperprolactinemia (HPRL), which in turn causes sexual dysfunction in patients. Peony-Glycyrrhiza Decoction (PGD) enhanced dopamine D2 receptors (DRD2) and dopamine transporter (DAT) and significantly reversed the expression of DRD2 and DAT. Therefore, we hypothesized that PGD might effectively improve hyperprolactinemia and alleviate sexual dysfunction in patients. METHODS: We performed an 8-week randomized controlled study on 62 subjects with schizophrenia who were randomized into two groups. The experimental group was treated with the PGD intervention, and the control group did not receive treatment. The primary outcome indicators were the levels of sex hormones and the total Arizona Sexual Experience Scale (ASEX) score. RESULTS: There was a significant difference in PRL levels between the two groups at weeks 4 and 8. From the beginning to the end of the experiment, there was a significant increase in PRL levels in the control group, while there was no significant change in the experimental group. The ASEX scale assessed sexual function in both groups, and patients in the experimental group showed an improvement in sexual function at week 8. During the experiment, the two groups found no differences between Positive and Negative Syndrome Scale (PANSS) scores and Treatment Emergent Symptom Scale (TESS) scores. CONCLUSION: PGD significantly improved the patient’s sexual function but was less effective in reducing prolactin levels and may prevent further increases in prolactin levels.
format Online
Article
Text
id pubmed-10120814
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-101208142023-04-22 Peony-Glycyrrhiza Decoction for Antipsychotic-Related Hyperprolactinemia in Patients with Schizophrenia: A Randomized Controlled Trial Wang, Zhongbao Zheng, Yunshao Fan, Yunli Fan, Yunming Su, Xianbiao Wang, Bingrui Li, Jing Chen, Diancai Sun, Fengxia Li, Shen Ma, Jiashu Li, Xianwei Bai, Ludong Li, Ranran Neuropsychiatr Dis Treat Clinical Trial Report BACKGROUND: Most antipsychotic drugs are dopamine receptor antagonists that usually lead to abnormal increases in prolactin concentrations and the development of hyperprolactinemia (HPRL), which in turn causes sexual dysfunction in patients. Peony-Glycyrrhiza Decoction (PGD) enhanced dopamine D2 receptors (DRD2) and dopamine transporter (DAT) and significantly reversed the expression of DRD2 and DAT. Therefore, we hypothesized that PGD might effectively improve hyperprolactinemia and alleviate sexual dysfunction in patients. METHODS: We performed an 8-week randomized controlled study on 62 subjects with schizophrenia who were randomized into two groups. The experimental group was treated with the PGD intervention, and the control group did not receive treatment. The primary outcome indicators were the levels of sex hormones and the total Arizona Sexual Experience Scale (ASEX) score. RESULTS: There was a significant difference in PRL levels between the two groups at weeks 4 and 8. From the beginning to the end of the experiment, there was a significant increase in PRL levels in the control group, while there was no significant change in the experimental group. The ASEX scale assessed sexual function in both groups, and patients in the experimental group showed an improvement in sexual function at week 8. During the experiment, the two groups found no differences between Positive and Negative Syndrome Scale (PANSS) scores and Treatment Emergent Symptom Scale (TESS) scores. CONCLUSION: PGD significantly improved the patient’s sexual function but was less effective in reducing prolactin levels and may prevent further increases in prolactin levels. Dove 2023-04-17 /pmc/articles/PMC10120814/ /pubmed/37089913 http://dx.doi.org/10.2147/NDT.S408314 Text en © 2023 Wang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Clinical Trial Report
Wang, Zhongbao
Zheng, Yunshao
Fan, Yunli
Fan, Yunming
Su, Xianbiao
Wang, Bingrui
Li, Jing
Chen, Diancai
Sun, Fengxia
Li, Shen
Ma, Jiashu
Li, Xianwei
Bai, Ludong
Li, Ranran
Peony-Glycyrrhiza Decoction for Antipsychotic-Related Hyperprolactinemia in Patients with Schizophrenia: A Randomized Controlled Trial
title Peony-Glycyrrhiza Decoction for Antipsychotic-Related Hyperprolactinemia in Patients with Schizophrenia: A Randomized Controlled Trial
title_full Peony-Glycyrrhiza Decoction for Antipsychotic-Related Hyperprolactinemia in Patients with Schizophrenia: A Randomized Controlled Trial
title_fullStr Peony-Glycyrrhiza Decoction for Antipsychotic-Related Hyperprolactinemia in Patients with Schizophrenia: A Randomized Controlled Trial
title_full_unstemmed Peony-Glycyrrhiza Decoction for Antipsychotic-Related Hyperprolactinemia in Patients with Schizophrenia: A Randomized Controlled Trial
title_short Peony-Glycyrrhiza Decoction for Antipsychotic-Related Hyperprolactinemia in Patients with Schizophrenia: A Randomized Controlled Trial
title_sort peony-glycyrrhiza decoction for antipsychotic-related hyperprolactinemia in patients with schizophrenia: a randomized controlled trial
topic Clinical Trial Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120814/
https://www.ncbi.nlm.nih.gov/pubmed/37089913
http://dx.doi.org/10.2147/NDT.S408314
work_keys_str_mv AT wangzhongbao peonyglycyrrhizadecoctionforantipsychoticrelatedhyperprolactinemiainpatientswithschizophreniaarandomizedcontrolledtrial
AT zhengyunshao peonyglycyrrhizadecoctionforantipsychoticrelatedhyperprolactinemiainpatientswithschizophreniaarandomizedcontrolledtrial
AT fanyunli peonyglycyrrhizadecoctionforantipsychoticrelatedhyperprolactinemiainpatientswithschizophreniaarandomizedcontrolledtrial
AT fanyunming peonyglycyrrhizadecoctionforantipsychoticrelatedhyperprolactinemiainpatientswithschizophreniaarandomizedcontrolledtrial
AT suxianbiao peonyglycyrrhizadecoctionforantipsychoticrelatedhyperprolactinemiainpatientswithschizophreniaarandomizedcontrolledtrial
AT wangbingrui peonyglycyrrhizadecoctionforantipsychoticrelatedhyperprolactinemiainpatientswithschizophreniaarandomizedcontrolledtrial
AT lijing peonyglycyrrhizadecoctionforantipsychoticrelatedhyperprolactinemiainpatientswithschizophreniaarandomizedcontrolledtrial
AT chendiancai peonyglycyrrhizadecoctionforantipsychoticrelatedhyperprolactinemiainpatientswithschizophreniaarandomizedcontrolledtrial
AT sunfengxia peonyglycyrrhizadecoctionforantipsychoticrelatedhyperprolactinemiainpatientswithschizophreniaarandomizedcontrolledtrial
AT lishen peonyglycyrrhizadecoctionforantipsychoticrelatedhyperprolactinemiainpatientswithschizophreniaarandomizedcontrolledtrial
AT majiashu peonyglycyrrhizadecoctionforantipsychoticrelatedhyperprolactinemiainpatientswithschizophreniaarandomizedcontrolledtrial
AT lixianwei peonyglycyrrhizadecoctionforantipsychoticrelatedhyperprolactinemiainpatientswithschizophreniaarandomizedcontrolledtrial
AT bailudong peonyglycyrrhizadecoctionforantipsychoticrelatedhyperprolactinemiainpatientswithschizophreniaarandomizedcontrolledtrial
AT liranran peonyglycyrrhizadecoctionforantipsychoticrelatedhyperprolactinemiainpatientswithschizophreniaarandomizedcontrolledtrial